Literature DB >> 11753603

Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.

G M Rigolin1, R Bigoni, R Milani, F Cavazzini, M G Roberti, A Bardi, P Agostini, M Della Porta, A Tieghi, N Piva, A Cuneo, G Castoldi.   

Abstract

At diagnosis, approximately half of myelodysplastic (MDS) patients presents a normal karyotype by conventional cytogenetic analysis (CCA). Fluorescent in situ hybridization (FISH) is more sensitive than CCA allowing for the detection of minor clones and of submicroscopic lesions. We have analyzed by FISH 101 MDS patients with normal karyotype for the occurrence of the abnormalities which are most frequently observed in MDS (ie -5/5q-, -7/7q-, +8, 17p-). In 18 patients, 15 to 32% of interphase cells were found to carry one FISH abnormality. Six patients presented trisomy 8, five had del(5)(q31), five del(7)(q31), one monosomy 7 and one del(17)(p13). FISH abnormalities were more frequently observed among patients with an increased percentage of bone marrow blasts (P = 0.001). FISH abnormalities were also associated with a higher rate of progression into AML (13/18 vs 12/83, P < 0.001) and were predictive for a worse prognosis (P < 0.001). Multivariate analysis indicated that FISH positivity and IPSS risk group were independent predictors for a poor survival (P = 0.0057 and 0.0123, respectively) and for leukemic transformation (P = 0.0006 and 0.035, respectively). Leukemic transformation in FISH-positive patients was associated in all cases with an expansion of the abnormal clone. Our data demonstrated that a significant proportion of MDS patients with normal karyotype presented, if analyzed by FISH, clones of cytogenetically abnormal cells which played a determinant role in the progression of the disease. The presence of FISH abnormalities identified a group of MDS patients with normal karyotype characterized by an inferior prognosis.

Entities:  

Mesh:

Year:  2001        PMID: 11753603     DOI: 10.1038/sj.leu.2402293

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Authors:  Friederike Braulke; Uwe Platzbecker; Catharina Müller-Thomas; Katharina Götze; Ulrich Germing; Tim H Brümmendorf; Florian Nolte; Wolf-Karsten Hofmann; Aristoteles A N Giagounidis; Michael Lübbert; Peter L Greenberg; John M Bennett; Francesc Solé; Mar Mallo; Marilyn L Slovak; Kazuma Ohyashiki; Michelle M Le Beau; Heinz Tüchler; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Katayoon Shirneshan; Carlo Aul; Reinhard Stauder; Wolfgang R Sperr; Peter Valent; Christa Fonatsch; Lorenz Trümper; Detlef Haase; Julie Schanz
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

Review 2.  Myelodysplastic syndromes: an update on molecular pathology.

Authors:  Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

3.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

4.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

5.  Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome.

Authors:  Jin-Quan Wen; Hai-Lin Feng; Xu-Qing Wang; Ju-Ping Pang
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

6.  Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis.

Authors:  K-E T Codispoti; L Depalma
Journal:  Int J Lab Hematol       Date:  2009-12-23       Impact factor: 2.877

7.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

Review 8.  The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores.

Authors:  O Căzăceanu; Am Vlădăreanu; H Bumbea; M Begu; M Onisai; C Enache
Journal:  J Med Life       Date:  2014-09-25

9.  Comparative assessment of conventional chromosomal analysis and fluorescence in situ hybridization in the evaluation of suspected myelodysplastic syndromes: a single institution experience.

Authors:  Denyo Adjoa Zakhia; Olga Voronel; Feras Zaiem; Kunil Raval; Jay Yang; Deborah Schloff; Anwar N Mohamed; Ali M Gabali
Journal:  Avicenna J Med       Date:  2019 Apr-Jun

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.